OKYO PHARMA LTD Stock Price, News & Analysis

Goldman Small Cap Research has published a new research report on OKYO Pharma (NASDAQ:OKYO), highlighting its potential in the ophthalmic drugs segment. OKYO's lead drug candidate OK-101 has completed a 240-patient Phase 2 trial in Dry Eye Disease (DED) and is currently being evaluated in a 48-patient Phase 2 trial for Neuropathic Corneal Pain (NCP).

The company is notable for being the first to receive FDA approval for NCP clinical trials and launch a specific NCP patient trial. Goldman estimates the potential NCP market size at $6.4 billion, based on 160,000 US potential patients, contingent on receiving Orphan Drug designation. The report suggests OKYO could attract potential joint venture partners or acquirers in 2026/2027, with several milestones expected in 2025.

OKYO Pharma provided updates on its clinical trials and financial results for the six months ended September 30, 2024. The company expects to complete enrollment of 48 patients in its Phase 2a trial of OK-101 for Neuropathic Corneal Pain (NCP) by Q2 2025, with top-line data expected in Q4 2025.

Earlier in January 2024, OKYO reported positive top-line data from its Phase 2b trial of OK-101 for Dry Eye Disease (DED). The drug showed statistically significant benefits in total conjunctival staining by Day 29 and improved symptoms like burning/stinging and blurred vision. The safety profile was favorable, with TEAEs similar to placebo.

Financially, OKYO reported total assets of $2.8 million as of September 2024, including $1.0 million in cash, with an additional $1.8 million received post-period. The company's comprehensive loss decreased to $3.1 million compared to $8.5 million in the same period last year.

OKYO Pharma (NASDAQ: OKYO) has secured $1.4 million in non-dilutive funding to advance its innovative pipeline, particularly focusing on its lead program OK-101 for treating neuropathic corneal pain (NCP). The company, which develops therapies for NCP - a severe ocular condition without FDA-approved treatments - and inflammatory dry eye disease (DED), will use this funding to support ongoing research and development initiatives.

The funding strengthens OKYO's ability to progress its development programs without diluting shareholder value. CEO Dr. Gary S. Jacob emphasized that this financial boost will contribute significantly to their mission of developing groundbreaking treatments for ophthalmic diseases while maintaining fiscal responsibility and creating value for shareholders.

OKYO Pharma (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on treating neuropathic corneal pain and inflammatory dry eye disease, announces its participation in the 4th Annual Virtual BTIG Ophthalmology Day on December 2nd, 2024. CEO Gary S. Jacob will engage in one-on-one meetings and lead a fireside chat from 2:40-3:15pm.

The event will feature over 20 medical technology and biotechnology companies, discussing latest developments in ophthalmic technologies and therapeutics. OKYO is developing treatments for NCP, which currently lacks FDA-approved therapies, and DED, representing a multi-billion-dollar market opportunity.

RedChip Companies announces the airing of interviews with MUSQ Global Music Industry ETF (NYSE:MUSQ) and OKYO Pharma on Bloomberg TV. David Schulhof, MUSQ's Founder and CEO, discusses how their ETF provides exposure to the global music ecosystem through the MUSQ Global Music Industry Index (MUSQIX), covering music streaming, content, distribution, live events, radio, and equipment. Goldman Sachs projects industry revenue to reach $163.7B by 2030.

OKYO Pharma's CEO Gary Jacob discusses their Phase 2 clinical trial of OK-101, a novel non-opioid topical treatment for neuropathic corneal pain (NCP). The trial, initiated October 16, 2024, at Tufts Medical Center, aims to evaluate OK-101's effectiveness in treating NCP caused by dry eye disease, surgery, or infections.

OKYO Pharma (NASDAQ: OKYO) announces its participation in the 10th International Tear Film & Ocular Surface Society Conference in Venice, Italy from October 30 to November 2, 2024. The company will present results from their dry eye disease trial and discuss their ongoing Phase 2 trial of OK-101 for Neuropathic Corneal Pain treatment at Tufts Medical Center.

Chief Scientific Officer Dr. Raj Patil will present 'Efficacy and Safety Results of First-in-Human Phase 2 Trial of OK-101 in Dry Eye Patients' during Poster Session III on November 2, 2024. The company aims to develop treatments for both neuropathic corneal pain, which currently lacks FDA-approved therapy, and inflammatory dry eye disease, representing a multi-billion-dollar market opportunity.

OKYO Pharma (NASDAQ: OKYO) has initiated its Phase 2 clinical trial for OK-101, announcing the first patient dosing in a study targeting Neuropathic Corneal Pain (NCP). The trial is designed as a double-masked, randomized, 12-week placebo-controlled study involving 48 patients with NCP confirmed via confocal microscopy. OK-101 is a novel, non-opioid therapeutic candidate and the first drug to receive FDA IND approval specifically for NCP treatment. The study is being conducted at a single center under the leadership of Dr. Pedram Hamrah at Tufts Medical Center, a leading expert in NCP treatment and research.

OKYO Pharma has initiated a Phase 2 clinical trial for OK-101 to treat Neuropathic Corneal Pain (NCP), a rare ocular condition with no FDA-approved treatments. The trial, led by Dr. Pedram Hamrah at Tufts Medical Center, will enroll 48 patients in a 12-week, double-masked, randomized, placebo-controlled study. The primary endpoint is pain relief measured by the Visual Analog Scale (VAS).

OK-101 recently showed promising results in a Phase 2 dry eye disease trial, demonstrating statistically significant improvements in symptoms like stinging/burning and ocular pain. It also reduced neuropathic corneal pain in a mouse model. OKYO Pharma is the first company to receive FDA approval for an Investigational New Drug (IND) application for NCP, which is listed as an orphan disease by the National Organization for Rare Disorders (NORD).

OKYO Pharma (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on developing innovative ocular therapies, has announced a significant insider purchase. Gabriele Cerrone, the Executive Chairman, through Panetta Partners , acquired 50,000 ordinary shares at $1.03 per share on NASDAQ. This transaction has increased Cerrone's total shareholding to 9,851,570 shares, representing 29.12% of the company's issued share capital.

OKYO Pharma specializes in treatments for inflammatory dry eye disease (DED), a multi-billion-dollar market, and neuropathic corneal pain (NCP), an ocular condition currently lacking FDA-approved therapies. This insider purchase may signal confidence in the company's future prospects and ongoing clinical developments.